SAN DIEGO, May 20 /PRNewswire/ -- Biocept, Inc. ("Biocept"), an emerging leader in rare cell capture, announced today that the U.S. Patent and Trademark Office has issued a patent for Biocept's cell separation technology using a microfluidic device. U.S. patent #7,695,956 entitled "Device for Cell Separation and Analysis and Method of Using" protects Biocept's microflow device to isolate cells from a bodily fluid using a flow path where straight-line flow is interrupted by transverse posts arranged in a random pattern. Sequestering agents, such as antibodies, are used to immobilize the cells in the cavity of the device. Cells can then be analyzed inside the microchannel using morphological, immunohistochemical, or fluorescent in situ hybridization (FISH) tests, or the cells can be released from the channel for molecular analysis following extraction of DNA.
"This patent establishes Biocept's leadership position in using a microfluidic device to capture and analyze rare cells for prenatal or cancer applications," said Stephen M. Coutts, President and CEO of Biocept. "We are using this invention to develop innovative proprietary tests in which we capture and analyze circulating tumor cells from a blood sample from cancer patients. These circulating tumor cells provide genetic information about the patient's disease and can potentially guide the clinicians in making therapeutic choices to maximize patient response. We look forward to bringing this technology through to commercialization and making personalized medicine a reality for cancer patients and their families."
About Biocept
Biocept, whose focus is in cell separation technology, develops novel diagnostic assays for personalized medicine in detection and monitoring of recurrent cancer. Biocept's CEE™ Cell Enrichment and Extraction platform combines sophisticated attachment chemistry with mathematically modeled fluid dynamics to enable earlier, accurate and less invasive diagnoses. Isolation, purification and genetic analysis of rare cells, such as circulating tumor cells, are managed within our state-of-the-art CLIA-accredited laboratory. The clinical laboratory is accredited by the College of American Pathologists (CAP) and holds licenses in California and several other states.
SOURCE Biocept, Inc.
Advertisement
"This patent establishes Biocept's leadership position in using a microfluidic device to capture and analyze rare cells for prenatal or cancer applications," said Stephen M. Coutts, President and CEO of Biocept. "We are using this invention to develop innovative proprietary tests in which we capture and analyze circulating tumor cells from a blood sample from cancer patients. These circulating tumor cells provide genetic information about the patient's disease and can potentially guide the clinicians in making therapeutic choices to maximize patient response. We look forward to bringing this technology through to commercialization and making personalized medicine a reality for cancer patients and their families."
Advertisement
About Biocept
Biocept, whose focus is in cell separation technology, develops novel diagnostic assays for personalized medicine in detection and monitoring of recurrent cancer. Biocept's CEE™ Cell Enrichment and Extraction platform combines sophisticated attachment chemistry with mathematically modeled fluid dynamics to enable earlier, accurate and less invasive diagnoses. Isolation, purification and genetic analysis of rare cells, such as circulating tumor cells, are managed within our state-of-the-art CLIA-accredited laboratory. The clinical laboratory is accredited by the College of American Pathologists (CAP) and holds licenses in California and several other states.
SOURCE Biocept, Inc.
